Follow The Filings

ZBIO Zenas Biopharma Inc.

Health Care, filed as ZENAS BIOPHARMA INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 1 exit

In 2026 Q2 Nathan Fischel sold out of Zenas Biopharma.

Who owns ZBIO

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management exited 2026 Q2 Last 2026 Q1 0.19% Exit −0.19% 42,500 $831K History

0 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by ZBIO's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ZBIO insider trades
  • $11.4M bought by 4 insiders
  • None no sales outside a trading plan
  • None no planned (10b5-1) sales
  1. Leon O Moulder Jr. CEO
    Buy
    $1M 60,000 shares at $16.88 +163% to stake
    Traded May 18 Filed May 18
    ↗
  2. Leon O Moulder Jr. CEO
    Buy
    $1.1M 60,000 shares at $17.79 +3.5% to stake
    Traded Apr 28–29 Filed Apr 29
    ↗
  3. Hongbo Lu Director
    Buy
    $70K 3,768 shares at $18.63 +0.9% to stake
    Traded Mar 31 Filed Apr 2
    ↗
  4. Fairmount Funds Management LLC Director, +3 joint filers
    Buy
    $3M 150,000 shares at $20.00 +6.8% to stake
    Traded Mar 31 Filed Apr 1
    ↗
  5. Leon O Moulder Jr. CEO
    Buy
    $1M 54,000 shares at $18.91 +3.2% to stake
    Traded Mar 30–31 Filed Mar 31
    ↗
  6. Hongbo Lu Director
    Buy
    $1.5M 75,000 shares at $20.00 +22% to stake
    Traded Mar 31 Filed Mar 31
    ↗
  7. Hongbo Lu Director
    Buy
    $585K 25,985 shares at $22.50 +8.1% to stake
    Traded Feb 11 Filed Feb 13
    ↗
  8. Patricia L Allen Director
    Buy
    $500K 19,860 shares at $25.16 New stake
    Traded Feb 12–13 Filed Feb 13
    ↗
  9. Leon O Moulder Jr. CEO
    Buy
    $1M 57,000 shares at $17.96 +16% to stake
    Traded Feb 2 Filed Feb 3
    ↗
  10. Leon O Moulder Jr. CEO
    Buy
    $1.6M 100,000 shares at $16.39 +38% to stake
    Traded Jan 7–9 Filed Jan 9
    ↗
  11. Jason Raleigh Nunn Director
    Buy
    $1.2M 63,158 shares at $19.00 +5.7% to stake
    Traded Oct 9, 2025 Filed Oct 14, 2025
    ↗
  12. Sr One Capital Management, LLC 10% owner, +1 joint filer
    Buy
    $2.4M 126,315 shares at $19.00 +7.1% to stake
    Traded Oct 9, 2025 Filed Oct 14, 2025
    ↗
  13. Patrick G Enright Director
    Buy
    $2.3M 117,255 shares at $19.19
    Traded Oct 9, 2025 Filed Oct 14, 2025
    ↗
  14. Leon O Moulder Jr. See Remarks
    Buy
    $770K 36,928 shares at $20.85 New stake
    Traded Oct 7, 2025 Filed Oct 9, 2025
    ↗
  15. Fairmount Funds Management LLC Director, +3 joint filers
    Buy
    $6M 316,219 shares at $19.00 +17% to stake
    Traded Oct 7, 2025 Filed Oct 9, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 2 stock grants.

SEC filings

Recent issuer filings from EDGAR, 21 shown.

Filed Form Detail Links
8-K 7.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13D/A — Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 2.02,5.02,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02,5.02,5.07,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13D — Filing Doc
SCHEDULE 13D/A — Filing Doc
8-K 1.01,2.03,8.01,9.01 Filing Doc
424B5 Filing Doc
424B5 Filing Doc
424B5 Filing Doc
424B5 Filing Doc
DEF 14A Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
DEFA14A Filing Doc
8-K 5.02,9.01 Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2024 FY2025
Revenue $5M $10M
Net income -$156.99M -$377.74M
Net margin * -3139.8% -3777.4%

Balance sheet

Metric FY2024 FY2025
Total current assets $355.92M $351.17M
Total non-current assets * $14.04M $32.47M
Total assets $369.97M $383.64M
Total current liabilities $57.29M $62.65M
Total non-current liabilities * $0.218M $78.85M
Total equity $312.46M $242.14M

Cash flow

Metric FY2024 FY2025
Cash from operations -$119.67M -$172.33M
Cash from investing -$30.55M -$251.89M
Cash from financing $412.96M $215.28M
Net change in cash $262.89M -$209.19M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.